痛风治疗新药——选择性尿酸重吸收抑制剂lesinurad(4)
[4] Tausche AK， Alten R， Dalbeth N， et al. SAT0307. Lesinurad monotherapy in gout patients intolerant to xanthine oxidase inhibitors (LIGHT)： a randomized， double-blind， placebocontrolled， 6-month phase III clinical trial [J]. Ann Rheum Dis， 2015， 74(Suppl 2)： 769.
[5] Saag K， Fitz-Patrick D， Kopicko J， et al. FRI0320. Lesinurad， a selective uric acid reabsorption inhibitor， in combination with allopurinol： results from a phase III study in gout patients having an inadequate response to standard of care (CLEAR 1)[J]. Ann Rheum Dis， 2015， 74(Suppl 2)： 540.
[6] Bardin T， Keenan R， Khanna P， et al. FRI0333. Lesinurad， a selective uric acid reabsorption inhibitor， in combination with allopurinol： results from a phase III study in gout patients having an inadequate response to standard of care (CLEAR 2)[J]. Ann Rheum Dis， 2015， 74(Suppl 2)： 545.
[7] Dalbeth N， Jones G， Terkeltaub R， et al. SAT0329. Lesinurad， a novel selective uric acid reabsorption inhibitor， in combination with febuxostat， in patients with tophaceous gout： the CRYSTAL phase III clinical trial [J]. Ann Rheum Dis， 2015， 74(Suppl 2)： 778.
[8] Dalbeth N， Jones G， Terkeltaub R， et al. Abstract number 2352. Efficacy and safety in patients with tophaceous gout receiving lesinurad and febuxostat combination therapy： interim analysis of an extension study [J]. Arthritis Rheumatol， 2015， 67(Suppl 10)： 2836-2837. (刘磊 杨雪 梁敏锐 朱小霞 张炯 邹和建 薛愉)
[5] Saag K， Fitz-Patrick D， Kopicko J， et al. FRI0320. Lesinurad， a selective uric acid reabsorption inhibitor， in combination with allopurinol： results from a phase III study in gout patients having an inadequate response to standard of care (CLEAR 1)[J]. Ann Rheum Dis， 2015， 74(Suppl 2)： 540.
[6] Bardin T， Keenan R， Khanna P， et al. FRI0333. Lesinurad， a selective uric acid reabsorption inhibitor， in combination with allopurinol： results from a phase III study in gout patients having an inadequate response to standard of care (CLEAR 2)[J]. Ann Rheum Dis， 2015， 74(Suppl 2)： 545.
[7] Dalbeth N， Jones G， Terkeltaub R， et al. SAT0329. Lesinurad， a novel selective uric acid reabsorption inhibitor， in combination with febuxostat， in patients with tophaceous gout： the CRYSTAL phase III clinical trial [J]. Ann Rheum Dis， 2015， 74(Suppl 2)： 778.
[8] Dalbeth N， Jones G， Terkeltaub R， et al. Abstract number 2352. Efficacy and safety in patients with tophaceous gout receiving lesinurad and febuxostat combination therapy： interim analysis of an extension study [J]. Arthritis Rheumatol， 2015， 67(Suppl 10)： 2836-2837. (刘磊 杨雪 梁敏锐 朱小霞 张炯 邹和建 薛愉)